[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.

624.O2.6 Lymphoma - Therapy with Biologic Agents, excluding Pre-Clinical Models: Immunotherapy for Indolent Lymphoma

Program: Oral and Poster Abstracts
Type: Oral
Monday, December 6, 2010: 10:30 AM-12:00 PM
311 EFGH (Orange County Convention Center)
Barbara Pro, MD, Fox Chase Cancer Center and John P. Leonard, MD, Weill Cornell Medical College
10:30 AM
Combination Biologic Therapy as Initial Treatment for Follicular Lymphoma:  Initial Results From CALGB 50701 - a Phase II Trial of Extended Induction Epratuzumab (anti-CD22) and Rituximab (anti-CD20)

Barbara Grant, MD1, John P. Leonard, MD2, Jeffrey L Johnson3*, Lale Kostakoglu4*, Eric D. Hsi, MD5, John C. Byrd, MD6, Jeffrey A. Jones, MD, MPH7, Sin-Ho Jung8* and Bruce D. Cheson, MD9

1Medicine, Vermont Cancer Center, University of Vermont, Burlington, VT
2Center for Lymphoma and Myeloma, Weill Cornell Medical College, New York, NY
3Duke Comprehensive Cancer Center, Duke University, Durham, NC
4Dept. of Radiology, Mount Sinai Medical Center, New York, NY
5Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH
6The Ohio State University, Columbus, OH
7The Ohio State University
8Department of Biostatistics & Bioinformatics, Duke University, Duke University, NC
9Division of Hematology and Oncology, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington, DC

10:45 AM
A Phase 2, Double-Blind, Placebo-Controlled Trial of Rituximab + Galiximab Vs Rituximab + Placebo In Advanced Follicular Non-Hodgkin’s Lymphoma (NHL)

Isabelle Bence-Bruckler, MD, FRCPC1*, David Macdonald, MD, FRCPC2, Patrick J Stiff, MD3, Byron McKinney, MS4*, Katherine L. Ruffner, MD4, Lynn Wilson5*, Margaret Whiteley, BSc4* and Brad S. Kahl, MD6

1General Campus - Hemotology, The University of Ottawa, The Ottawa Hospital, Ottawa, ON, Canada
2Hematology/Medicine, QEII Health Sciences Centre, Halifax, NS, Canada
3Loyola University Medical Center, Maywood, IL
4Biogen Idec, San Diego, CA
5Biogen Idec, Maidenhead, CA, United Kingdom
6Department of Medicine-Hematology/Oncology, University of Wisconsin, Madison, WI

11:00 AM
Vaccination with IgM but Not IgG Idiotype Prolongs Remission Duration In Follicular Lymphoma Patients

Stephen J. Schuster, MD1, Carlos F. Santos2*, Sattva S. Neelapu3, Donald Berry4*, Mihaela A. Popa2, Amy M. McCord2*, Elise A. Chong, BA1* and Larry W Kwak, MD, PhD3

1Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
2Biovest International, Inc., Tampa, FL
3Lymphoma & Myeloma, U.T. M.D. Anderson Cancer Center, Houston, TX
4Division of Quantitative Sciences, Berry Consultants, LLC/M.D. Anderson Cancer Center, College Station, TX

11:15 AM
Inotuzumab Ozogamicin (CMC-544) In Patients with Indolent B-Cell NHL That Is Refractory to Rituximab Alone, Rituximab and Chemotherapy, or Radioimmunotherapy: Preliminary Safety and Efficacy From a Phase 2 Trial

Andre Goy, MD1, Joseph Leach2*, W. Christopher Ehmann, MD3, Kiyoshi Ando, MD, PhD4, Kiyohiko Hatake, MD, PhD5, Kensei Tobinai, MD, PhD6, Tatyana Feldman, MD7, Steven Hua8*, Angela Volkert9*, Erik R Vandendries, MD, PhD9* and Michinori Ogura, MD, PhD10

1John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ
2Park Nicollet Frauenshuh Cancer Institute, St. Louis Park, MN
3M.S. Hershey Medical Center, Penn State Cancer Institute, Hershey, PA
4Hematology/Oncology, Tokai University Hospital, Isehara, Japan
5Department of Medical Oncology and Hematology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
6Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan
7The Cancer Center at Hackensack University Medical Center, Hackensack, NJ
8Pfizer Inc., Cambridge, MA
9Pfizer Inc, Cambridge, MA
10Department of Hematology and Oncology, Nagoya Daini Red Cross Hospital, Nagoya, Japan

11:30 AM
Phase II/III Study of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab (R-CHOP) Versus Biweekly CHOP with Rituximab (R-Bi-CHOP) In Untreated Advanced-Stage Indolent B-Cell Lymphoma: Japan Clinical Oncology Group (JCOG) 0203 TrialClinically Relevant Abstract

Takashi Watanabe, MD, PhD1*, Yasuo Morishima, MD, PhD2, Taro Shibata, MSc3*, Nobuo Maseki, MD, PhD4*, Tomohiro Kinoshita, MD, PhD5, Takayo Suzuki, MD, PhD6, Motoko Yamaguchi, MD, PhD7, Kiyoshi Ando, MD, PhD8, Michinori Ogura, MD, PhD9, Masafumi Taniwaki, MD, PhD10*, Naokuni Uike, MD, PhD11*, Kengo Takeuchi, MD, PhD12*, Shigeru Nawano, MD, PhD13*, Takashi Terauchi, MD, PhD14*, Kunihiro Tsukasaki, MD, PhD15, Tomomitsu Hotta, MD, PhD16 and Kensei Tobinai, MD, PhD17

1National Cancer Center Hospital, Tokyo, Japan
2Department of Hematology and Cell Therapy, Aichi Cancer Center Hospital, Nagoya, Japan
3JCOG Data Center, Clinical Trials and Practice Support Division, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan
4Department of Hematology, Saitama Cancer Center, Ina, Japan
5Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan
6Department of Hematology and Oncology, Shiga Medical Center for Adults, Moriyama, Japan
7Department of Hematology and Oncology, Mie University Graduate School of Medicine, Tsu, Japan
8Hematology/Oncology, Tokai University Hospital, Isehara, Japan
9Department of Hematology and Oncology, Nagoya Daini Red Cross Hospital, Nagoya, Japan
10Department of Molecular Hematology and Oncology, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan
11Hematology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
12Pathology Project for Molecular Targets, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan
13Center for Radiological Science, International University of Health and Welfare Mita Hopital, Tokyo, Japan
14Screening Technology and Development Division, Research Center for Cancer Prevention and Screening, National Cancer Center, Tokyo, Japan
15Department of Hematology and Molecular Medicine, Atomic Bomb Disease Institute, Nagasaki University Graduate School of Biomedical Science, Nagasaki, Japan
16National Hospital Organization Nagoya Medical Center, Nagoya, Japan
17Hematology and Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan

11:45 AM
Chlorambucil Plus Rituximab Produces Better Event-Free Survival in Comparison with Chlorambucil Alone in the Treatment of MALT Lymphoma: 5-Year Analysis of the 2-Arms Part of the IELSG-19 Randomized StudyClinically Relevant Abstract

Emanuele Zucca, MD1, Annarita Conconi, MD2, Giovanni Martinelli, MD3, Maurizio Martelli, MD4*, Catherine Thieblemont, MD5, Peter W Johnson, MD 6, Armando Lopez-Guillermo, MD7, Reda Bouabdallah, MD8*, Alessandra Tucci, MD9*, Umberto Vitolo, MD10, Bertrand Coiffier, MD, PhD11, Liliana Devizzi, MD12*, Fabrice Jardin, MD, PhD13*, Catherine Sebban, MD14*, Graziella Pinotti, MD15*, Franck Morschhauser, MD, PhD16*, Ruth Pettengell, FRACP, PhD17*, Andre Bosly, MD, PhD18, Emili Montserrat, MD19, Monica Bellei, MSc, PhD20*, Stefano A Pileri21, Christiane Copie-Bergman22*, Elias Campo, MD23*, Andrew Jack, PhD, MB24, Luca Mazzucchelli, MD25* and Franco Cavalli, MD1

1Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
2Division of Hematology, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy
3Division of Hematology, European Institute of Oncology, Milan, Italy
4Division of Hematology, ''Sapienza'' University, Rome, Italy
5Hospital Saint-Louis, Paris, France
6Faculty of Medicine, Cancer Research UK Centre, Southampton, United Kingdom
7Department of Hematology, Hospital Clínic, Barcelona, Spain
8Institut Paoli-Calmettes, Marseille, France
9Ematologia, Spedali Civili, Brescia, Italy
10Chair of Haematology, University of Torino, Torino, Italy
11Centre Hospitalier Lyon-Sud, Pierre-Benite, France
12Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
13Hematology, Centre Henri Becquerel, Rouen, France
14Onco-hematology, Centre Léon Bérard, Lyon, France
15Oncology unit, Az. Osp. VArese, Varese, Italy
16Hematology Department, Hôpital Claude Huriez, Lille, France
17Haematology, St George's University of London, London, United Kingdom
18Hematology, UCL Mont Godinne, Yvoir, Belgium
19Department of Hematology, Hospital Clinic, Barcelona, Spain
20Dipartimento di Oncologia ed Ematologia, Universita' di Modena e Reggio Emilia, Modena, Italy
21On the behalf of Italian Lymphoma Foundation (FIL), Hematology 2, San Giovanni Battista Hospital and University, Turin, Italy
22Pathology Department, Hopital Henri Mondor, Paris Créteil Cedex, France
23Department of Pathology, Hospital Clínic, Barcelona, Spain
24HMDS, St James's Institute of Oncology, Leeds, United Kingdom
25Istituto Cantonale di Patologia, Locarno, Switzerland

*signifies non-member of ASH